Drug Profile
Research programme: immuno-oncology therapeutics - Bristol-Myers Squibb/Cancer Research Institute/Parker Institute for Cancer Immunotherapy
Alternative Names: Cancer immunotherapies - Bristol-Myers Squibb/Cancer Research Institute/Parker Institute for Cancer ImmunotherapyLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Cancer Research Institute; Parker Institute for Cancer Immunotherapy
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Cancer in USA
- 28 Mar 2017 Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute enter into a clinical research collaboration to develop next-generation precision cancer immunotherapies
- 28 Mar 2017 Early research in Cancer in USA (unspecified route)